|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | ACAR: Adaptive Connectivity Aware Routing for Vehicular Ad Hoc Networks in City Scenarios显示文摘 | Qing Yang Alvin Lim Shuang Li Jian Fang Prathima Agrawal | 2010 | Mobile Networks and Applications2010，，1： | 3 |
| 2 | Prevalence and Impact of the Subclavian Steal Syndrome显示文摘 | Nicos Labropoulos Prathima Nandivada Kimon Bekelis | 2010 | Annals of Surgery2010，，1： | 2 |
| 3 | Fast Link Layer and Intra-Domain Handoffs for Mobil Internet显示文摘 | Jyh-Cheng Chen Prathima Agrawal | 2001 | Telcordia Technologies2001，，10： | 1 |
| 4 | Visualization for Access Control Policy Analysis Results Using Multi-level Grids显示文摘 | RAO Prathima GABRIEL Ghinita ELISA Bertino | 2009 | IEEE Transactions on Knowledge and Data Engineering2009，，9： | 1 |
| 5 | CD-3 positive extranodal T-cell lymphoma of nasal type with skin involvement显示文摘 | Singh G Prathima KJ | 2006 | Indian J Dermatol Venereol keprol2006，72，3： | 1 |
| 6 | Raman spectroscopy studies for diagnosis of cancers in human uterine cervix 显示文摘 | Krishna C M Prathima N B Malini R | 2006 | Vibrational Spectroscopy(S0924-2031)2006，41，1： | 1 |
| 7 | ACAR: Adaptive Connectivity Aware Routing for Vehicular Ad Hoc Networks in City Scenarios显示文摘 | Qing Yang Alvin Lim Shuang Li Jian Fang Prathima Agrawal | 2010 | Mobile Networks and Applications2010，，1： | 1 |
| 8 | Raman spectroscopy studies for diagnosis of cancers in human uterine cervix显示文摘 | C Murali Krishna N B Prathima R Malini | 2006 | Vibrational Spectroscopy2006，41，1： | 1 |
| 9 | Raman spectroscopy studies for diagnosis of cancers in human uterine cervix 显示文摘 | Krishna C Prathima NB Malini R | 2007 | Vibrat Spectroscopy2007，41，： | 1 |
| 10 | CO2 supplementation to domestic wastewater enhances microalgae lipid accumulation under mixotrophic microenvironment:Effect of sparging period and interval显示文摘 | M. Prathima Devi S. Venkata Mohan | | 0，，： | 1 |
| 11 | Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma:A systematic review显示文摘BACKGROUND Despite the use of current standard therapy,the prognosis of patients with unresectable hepatocellular carcinoma(HCC)is poor,with median survival times of 40 mo for intermediate HCC(Barcelona Clinic Liver Cancer[BCLC]stage B)and 6-8 mo for advanced HCC(BCLC stage C).Although patients with earlystage HCC are usually suitable for therapies with curative intention,up to 70% of patients experience relapse within 5 years.In the past decade,the United States Food and Drug Administration has approved different immunogenic treatment options for advanced HCC,the most common type of liver cancer among adults.Nevertheless,no treatment is useful in the adjuvant setting.Since 2007,the multikinase inhibitor sorafenib has been used as a first-line targeted drug to address the increased mortality and incidence rates of HCC.However,in 2020,the IMbrave150 trial demonstrated that combination therapy of atezolizumab(antiprogrammed death-ligand 1[PD-L1])and bevacizumab(anti-vascular endothelial growth factor[VEGF])is superior to sorafenib,a single anti-programmed death 1/PD-L1 antibody inhibitor used as an anti-cancer monotherapy for HCC treatment.AIM To conduct a systematic literature review to evaluate the evidence supporting the efficacy and safety of atezolizumab/bevacizumab as preferred first-line drug therapy over the conventional sorafenib or atezolizumab monotherapies,which are used to improve survival outcomes and reduce disease progression in patients with unresectable HCC and non-decompensated liver disease.METHODS A comprehensive literature review was conducted using the PubMed,Scopus,ScienceDirect,clinicaltrials.gov,PubMed Central,Embase,EuropePMC,and CINAHL databases to identify studies that met the inclusion criteria using relevant MeSH terms.This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and risk of bias(RoB)were assessed using the Cochrane RoB 2 tool and Sevis.RESULTS In the atezolizumab/bevacizumab group,an improvement in overall tumor response,reduction of disease progression,and longer progression-free survival were observed compared to monotherapy with either sorafenib or atezolizumab.Hypertension and proteinuria were the most common adverse events,and the rates of adverse events were comparable to those with the monotherapy.Of the studies,there were two completed trials and two ongoing trials analyzed using high quality and low bias.A more thorough analysis was only performed on the completed trials.CONCLUSION Treatment of HCC with atezolizumab/bevacizumab combination therapy was confirmed to be an effective first-line treatment to improve survival in patients with unresectable HCC and non-decompensated liver disease compared to monotherapy with either sorafenib or atezolizumab. | Faiza Ahmed Jennifer Onwumeh-Okwundu Zeynep Yukselen Maria-Kassandra Endaya Coronel Madiha Zaidi Prathima Guntipalli Vamsi Garimella Sravya Gudapati Marc Darlene Mezidor Kim Andrews Mohamad Mouchli Endrit Shahini | 2021 | World Journal of Gastrointestinal Oncology2021，13，11： | 1 |
| 12 | TeleMIP:Telecommunication-Eahanced Mobile IP Architecture for Fast Intradomain Mobility显示文摘 | Subir D Archan M Prathima A | 2000 | IEEE Personal Communications2000，7，4： | 1 |
| 13 | CELSR2–PSRC1–SORT1 gene expression and association with coronary artery disease and plasma lipid levels in an Asian Indian cohort显示文摘 | Prathima Arvind Jiny Nair Srikarthika Jambunathan Vijay V. Kakkar Jayashree Shanker | 2014 | Journal of Cardiology2014，，： | 1 |
| 14 | TeleMIP: Telecommunication-Enhanced Mobile IP Architecture for Fast Intradomain Mobility显示文摘 | Archan M Prathima A | 2000 | IEEE Personal Communications2000，7，4： | 1 |
| 15 | Elevated Alkaline Phosphatase in Infants With Parenteral Nutrition–Associated Liver Disease Reflects Bone Rather Than Liver Disease显示文摘 | Nandivada Prathima Potemkin Alexis K. Carlson Sarah J. Chang Melissa I. Cowan Eileen O’Loughlin Alison A. Gura Kathleen M. Puder Mark | 2015 | Journal of Parenteral and Enteral Nutrition2015，，： | 1 |
| 16 | Raman spectroscopy studies for diagnosis of cancers in human uterine cervix显示文摘 | C M Krishna N B Prathima R Malini | 2006 | ~ib Spectrose2006，41，1： | 1 |
| 17 | Potential of mixed microalgae to harness biodiesel from ecological water-bodies with simultaneous treatment显示文摘 | Venkata M S Prathima D M Mohanakrishna G | 2011 | Bioresource Technology2011，102，2： | 1 |
| 18 | A Survey of Energy Efficient Network Protocols for Wireless Networks显示文摘 | Christine E. Jones Krishna M. Sivalingam Prathima Agrawal Jyh Cheng Chen | 2001 | Wireless Networks2001，，4： | 1 |
| 19 | Potential of mixed microalgae to harnessbiodiesel from ecological water-bodies with simultaneous treatment 显示文摘 | Venkata Mohan S Prathima Devi M Mohanakrishna G Amarnath N Lenin Babu M Sarma PN | 2011 | Bioresour Technol2011，102，3： | 1 |
| 20 | Raman spectroscopy studies for diagnosis of cancers in human uterine cervix 显示文摘 | Murali Krishna C Prathima NB Malini R | 2006 | Vibrat Spectroscopy2006，41，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员